Ensacove (ensartinib capsules - Xcovery) — Cigna
Non-Small Cell Lung Cancer
Initial criteria
- Patient age ≥ 18 years; AND
- Patient has locally advanced or metastatic disease; AND
- Patient has anaplastic lymphoma kinase (ALK)-positive disease; AND
- The mutation was detected by an approved test; AND
- Patient has not previously received an ALK inhibitor
Approval duration
1 year